Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (NASDAQ: EVFM) has secured a five-year contract from the U.S. Department of Veterans Affairs to supply Phexxi®, a hormone-free contraceptive gel, starting December 15, 2020. This contract expands access to Phexxi for approximately 12 million lives, including patients in VA, Tricare, and other government health programs. The company has achieved coverage for 55% of commercial lives in the U.S., with nearly 8 million lives available at zero copay. This milestone marks a significant step in Evofem's mission to broaden access to women's reproductive health solutions.
Evofem Biosciences (NASDAQ: EVFM) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. A pre-recorded fireside chat featuring CEO Saundra Pelletier will be available on November 23 at 10:00 AM Eastern Time. The chat can be accessed on the company's website under the Events and Presentations section. Evofem focuses on women's sexual and reproductive health, with its product, Phexxi®, being the first hormone-free vaginal gel approved in the U.S. for pregnancy prevention.
Evofem Biosciences (NASDAQ: EVFM) will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 4:00 p.m. ET. The presentation can be accessed live and archived via the Evofem website. Evofem focuses on developing innovative products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi™, and is currently evaluating EVO100 in a Phase 3 trial for preventing urogenital infections.
Evofem Biosciences (NASDAQ: EVFM) reported financial results for Q3 2020, marking its first product sales of $0.3 million from the launch of Phexxi, a hormone-free contraceptive gel. Total operating expenses rose to $26.4 million, leading to a net loss of $29.9 million, or $(0.37) per share. The company secured a $25 million strategic investment from Adjuvant Capital to fund ongoing clinical trials and expand market access. Evofem initiated the EVOGUARD Phase 3 trial for EVO100, aimed at preventing chlamydia and gonorrhea infections in women.
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on November 9, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and business highlights. Interested parties can access the live webcast and related presentation on the Company's Investor page. Dial-in numbers for participation include (866) 503-5561 (U.S. toll-free) and (253) 336-2965. A telephone replay will be available shortly after the call through November 12, 2020, using conference ID 2639368.
Evofem Biosciences (NASDAQ: EVFM) will participate in a Virtual Investor KOL Roundtable on October 29, 2020, at 2:00 p.m. ET. CEO Saundra Pelletier and CMO Kelly Culwell will discuss women's reproductive health alongside expert Patricia Cason, RN, MS, FNP-BC. The event will delve into the current birth control landscape and contraceptive counseling. A live webcast will be available, with a replay accessible for three months.
Evofem Biosciences, Inc. (NASDAQ: EVFM) has commenced the pivotal Phase 3 EVOGUARD trial, enrolling its first patient to assess the efficacy and safety of EVO100 in preventing urogenital chlamydia and gonorrhea in women. With rising infection rates and increasing antibiotic resistance, the need for preventive measures like EVO100 has become critical. The trial will involve 1,730 women at risk of these infections. The FDA has granted EVO100 Fast Track Designation for chlamydia prevention, and it has also received Qualified Infectious Disease Product designation for gonorrhea.
Evofem Biosciences (NASDAQ: EVFM) has secured $25 million from the sale of unsecured convertible promissory notes to Adjuvant Capital. The notes, convertible at a price of $3.65 per share, will fund the upcoming Phase 3 clinical trial, EVOGUARD, for its product EVO100 targeting urogenital chlamydia and gonorrhea prevention in women. The company aims to expand market access for its non-hormonal contraceptive, Phexxi™, approved in May 2020. This partnership aligns with Adjuvant's mission to enhance contraceptive access globally.
Evofem Biosciences (NASDAQ: EVFM) announced new clinical trial data on Phexxi™ and EVO100 to be presented at major medical society meetings this October. The data includes insights into Phexxi users and factors affecting reinfection rates of chlamydia and gonorrhea, as well as findings related to the sexual impact of treatment. The AMPREVENCE trial enrolled 860 women, while the AMPOWER trial involved 1,384 participants, evaluating Phexxi's contraceptive efficacy. The company continues its publication strategy with nine abstracts to be presented this fall.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced a rescheduled virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference, set for September 17, 2020, from 1:20 p.m. to 1:50 p.m. ET. Interested parties can access the live and archived webcast on Evofem's website under the Investors section. The company focuses on developing innovative products in women's sexual and reproductive health, including its first product, Phexxi™, a hormone-free contraceptive gel. The firm is also advancing EVO100 into a Phase 3 clinical trial for STI prevention.